Overview

A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer

Status:
Completed
Trial end date:
2002-09-01
Target enrollment:
Participant gender:
Summary
This Phase III, multicenter, randomized, active-controlled, open-label trial is designed to evaluate the efficacy, safety, and pharmacokinetics of rhuMAb VEGF when combined with capecitabine compared with capecitabine alone in subjects with previously treated metastatic breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Bevacizumab